Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...

Obesity rates are down in this country. At the same time, more and more people are taking GLP-1 weight loss drugs. A coincidence? I think not. Despite that trend, a lot of employer-sponsored health ...

Howell star center Lilly Williams made her presence known early, guiding the Highlanders to the biggest win of the 2025-26 Michigan high school girls basketball regular season. The No. 6 Highlander ...

Add Yahoo as a preferred source to see more of our stories on Google. A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

It’s a good day to be the pharmaceutical giant Eli Lilly. Right now, Eli Lilly appears to be the leader in the GLP-1 race amid multiple difficult headwinds for Novo Nordisk. As of this writing, Novo ...

Eli Lilly has reported positive results from its phase 3b Together-PsO trial evaluating the combined use of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with plaque psoriasis and obesity or ...

Too much of a good thing? Participants taking the highest dose of Eli Lilly’s new GLP-1 drug lost an average of 28.7% of their body weight in a late-stage trial, putting it on track to be a ...

Eli Lilly has been busy building its drug pipeline for the future. The company currently sells the world's best-selling drug. It just bought Orna Therapeutics, an innovative drugmaker. Investing in ...

Eli Lilly (LLY) reported Q4 EPS of $7.54 versus $6.67 expected. Eli Lilly projected 2026 revenue of $80-83B. Eli Lilly’s Mounjaro revenue surged 110% to $7.4B in Q4. Zepbound revenue jumped 123% to $4 ...

Mon, February 16, 2026 at 7:00 PM UTC As of February 13, 2026, shares of Eli Lilly (NYSE:LLY) were trading at $1,040, just 5.8% below the stock's all-time high. Retail sentiment has turned decisively ...

Determined to avoid a repeat of the supply shortfalls that plagued early GLP-1 rollouts for obesity, Eli Lilly has amassed a sizable store of its oral weight loss candidate orforglipron. Specifically, ...